Abstract:1299 Since 1977, numerous studies have indicated the existence of a putative membrane-based estrogen receptor. However, the identity of this membrane-based estrogen receptor has not been established. Through an extensive homology search in Gene Bank, we recently identified and cloned a novel variant of ER-Α with a predicted molecular weight of 35.7 kDa. The transcript of this ER-Α variant is initiated from a previously unidentified promoter in the first intron of the original ER-Α gene. This ER-Α variant differs from the original ER-Α by lacking both transcriptional activation domains (AF-1 and AF-2) but retaining the dimerization, DNA-binding and partial ligand-binding domains. Its ligand-binding domain also possesses a unique 27 amino acid stretch that replaces the last 138 amino acids of the ER-Α. In transient transfection assays, this ER-Α variant exhibited no intrinsic transcriptional activity but strongly inhibited ligand-dependent and -independent transactivation activities mediated by the original ER-Α and ER-Β. Immunodetection and subcellular fractionation assays demonstrated that this ER-Α variant is expressed on the plasma membrane of mammary epithelial cells, and also in the cytoplasm and nucleus. In cells that express this ER-Α variant, 17Β-estradiol (E2) treatment activated a membrane-initiated effect of estrogen signaling by transiently activating the mitogen-activated protein kinase (MAPK) pathway that led to cell proliferation. Antiestrogens such as tamoxifen and ICI 182,780, however, strongly and persistently activated the MAPK pathway that then resulted in activation of the SAPK/JNK pathway. Immunohistochemistry analysis using a specific antibody aganst this ER-Α variant revealed that 26 of 38 cases (68%) breast cancer specimens examined express this ER-Αvariant on the plasma membrane and cytoplasm, and 12 out of 13 ER-negative breast caner specimens also express this ER-Α variant. Our findings demonstrate a physiologically important ER-Α variant that is involved in membrane-initiated estrogen signaling and suggest that aberrant expression of this ER-Α variant contributes to development of ER-positive and-negative human breast cancer.

Changes in Estrogen Receptor-Α Variant (Er-Α36) Expression During Mouse Ovary Development and Oocyte Meiotic Maturation

Estrogen receptor level and content change of IL-13 & TNF-α in different physiological stages in mice

The Predominant Proteins That React to the MC-20 Estrogen Receptor Alpha Antibody Differ in Molecular Weight Between the Mammary Gland and Uterus in the Mouse and Rat.

Expression of Estrogen Receptor, Progesterone Receptor and Leukemia Inhibitory Factor on Endometrium During Different Ovarian Stimulation Protocols in Mice

Identification, Cloning, and Expression of Human Estrogen Receptor-Α36, a Novel Variant of Human Estrogen Receptor-Α66

Estrogen-independent Effects of ER-α36 in ER-negative Breast Cancer

Expression of ERα36 in gastric cancer samples and their matched normal tissues.

ER-α36: a Novel Biomarker and Potential Therapeutic Target in Breast Cancer.

A Variant of Estrogen Receptor-Alpha, Her-Alpha 36: Transduction of Estrogen- and Antiestrogen-Dependent Membrane-Initiated Mitogenic Signaling

The therapeutic target of estrogen receptor-alpha36 in estrogen-dependent tumors

Transcriptional analysis of estrogen receptor alpha variant mRNAs in colorectal cancers and their matched normal colorectal tissues.

Dynamic Subcellular Localization of Estrogen Receptor Alpha During the First Two Cleavages of Mouse Preimplantation Embryos

Expression of ER-α36, a novel variant of estrogen receptor in endometrial carcinoma and its clinical significance.

Estrogen Receptors in Granulosa Cells Govern Meiotic Resumption of Pre-Ovulatory Oocytes in Mammals

Single-cell sequencing reveals the transcriptional alternations of 17β-estradiol suppressing primordial follicle formation in neonatal mouse ovaries.

ER-alpha36, a Novel Variant of ER-alpha, is Expressed in ER-positive and -Negative Human Breast Carcinomas.

Tentative Study on the Expression of Estrogen Receptor in Mouse Endometrium

A novel variant of estrogen receptor-alpha is expressed in ER-negative breast cancer and mediates membrane-initiated estrogen signaling

Expression of ER-{alpha}36, a Novel Variant of Estrogen Receptor {alpha}, and Resistance to Tamoxifen Treatment in Breast Cancer.

Quantitative Profiles of the Mrnas of ER-α and Its Novel Variant ER-α36 in Breast Cancers and Matched Normal Tissues

Estrogen Receptor Α Variant ERα46 Mediates Growth Inhibition and Apoptosis of Human HT-29 Colon Adenocarcinoma Cells in the Presence of 17Β-Oestradiol